These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 1933632)

  • 1. Preventing progression of coronary atherosclerosis: beyond cholesterol lowering.
    Waters D
    Can J Cardiol; 1991 Sep; 7(7):VIII-IX. PubMed ID: 1933632
    [No Abstract]   [Full Text] [Related]  

  • 2. Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial.
    Shimizu M; Koizumi J; Miyamoto S; Origasa H; Mabuchi H;
    Int J Cardiol; 2005 Mar; 99(3):395-401. PubMed ID: 15771919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol-lowering and coronary atherosclerosis: good news and bad news.
    Kreisberg RA
    Am J Med; 1996 Nov; 101(5):455-8. PubMed ID: 8948266
    [No Abstract]   [Full Text] [Related]  

  • 4. Extracorporeal LDL cholesterol removal: role of LDL-pheresis in combination with other hypolipidemic therapy to regress vascular disease.
    Saal SD; Gordon BR; Parker TS; Levine DM; Tyberg TI; Rubin AL
    Am J Med; 1989 Nov; 87(5N):68N-74N. PubMed ID: 2486551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol lowering and morbidity and mortality.
    LaRosa JC
    Curr Opin Lipidol; 1995 Feb; 6(1):62-5. PubMed ID: 7735718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors.
    Krobot KJ; Yin DD; Alemao E; Steinhagen-Thiessen E
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):37-45. PubMed ID: 15703504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Amirkabiria odorastissima mozaffarian on the development and progression of fatty streaks in hypercholesterolemic rabbits.
    Asgary S; Naderi G; Dashti G; Paknahad Z
    Phytother Res; 2004 May; 18(5):370-2. PubMed ID: 15173995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of coronary heart disease through cholesterol reduction.
    Grundy SM
    Am Fam Physician; 1997 May; 55(6):2250-8. PubMed ID: 9149652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cholesterol in atherosclerosis and its potential management by dietary fiber.
    Kohn IJ; Ribeiro LG
    Arq Bras Cardiol; 1991 Mar; 56(3):173-84. PubMed ID: 1653562
    [No Abstract]   [Full Text] [Related]  

  • 10. LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects.
    Gylling H; Miettinen TA
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):19-23. PubMed ID: 12125225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lipid modification on progression of coronary calcification.
    McCullough PA
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S115-9. PubMed ID: 16251246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS; Bissonnette S; Habib R; Boukas S;
    Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
    Yokoyama M; Origasa H;
    Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [All mortality by cause of death. The challenge of coronary prevention].
    Fernández-Cruz A
    Rev Esp Cardiol; 1998; 51 Suppl 6():23-9. PubMed ID: 10050141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
    Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lowering blood cholesterol to reduce coronary heart disease risk.
    Bradford RH; Rifkind BM
    Clin Lab Med; 1989 Mar; 9(1):1-6. PubMed ID: 2647369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on lipid-lowering therapy and LDL-cholesterol targets.
    Wiviott SD; Cannon CP
    Nat Clin Pract Cardiovasc Med; 2006 Aug; 3(8):424-36. PubMed ID: 16874355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of an extract containing esterol on plasma cholesterol and oxidants].
    Levy Y; Paster E; Dankner G; Ben-Amotz A; Brook JG
    Harefuah; 1998 Mar; 134(6):449-51, 503, 502. PubMed ID: 10909574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Summary of a dissertation. Cholesterol screening].
    Pirich C
    Wien Klin Wochenschr; 1990 Oct; 102(19):576-9. PubMed ID: 2281673
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.